CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

It’s time to turn the corner and redefine what print could be. The QR codes, personalization, and digital integration highlighted in emerging direct mail trends aren't just nice-to-have features ...

The randomized phase 3 REDEFINE 1 study (ClinicalTrials.gov Identifier: NCT05567796) evaluated the efficacy and safety of CagriSema in 3417 adults with obesity or overweight with 1 or more ...